铂类联合帕博利珠单抗对比铂类联合纳武利尤单抗-伊匹木单抗一线治疗日本晚期非小细胞肺癌的III期随机试验
JCOG2007是一项在日本48家医院开展的开放标签、多中心、随机III期试验,比较铂类化疗联合帕博利珠单抗与铂类化疗联合纳武利尤单抗-伊匹木单抗一线治疗晚期非小细胞肺癌的疗效与安全性。因纳武利尤单抗-伊匹木单抗组治疗相关死亡比例较高(148例中11例,7%),提前终止入组,最终入组295例。主要终点总生存期在两组间无显著差异,纳武利尤单抗-伊匹木单抗组3级及以上非血液学不良事件发生率更高。
要点
- 纳武利尤单抗-伊匹木单抗联合铂类化疗组治疗相关死亡比例达7%,导致试验提前终止入组。
- 纳武利尤单抗-伊匹木单抗组3级及以上非血液学不良事件发生率更高(60% vs 41%)。
核心结论
- 安全性和疗效数据提示,对于晚期非小细胞肺癌一线治疗,纳武利尤单抗-伊匹木单抗联合铂类化疗相对于帕博利珠单抗联合铂类化疗的获益-风险特征不利,但最终结论有待总生存期更新分析。
研究设计与样本
- 开放标签、多中心、随机III期试验,在日本48家医院开展。
- 入组标准为20岁及以上、既往未经治疗的晚期非小细胞肺癌、ECOG体能状态0或1,排除已知驱动基因阳性患者。
- 患者按1:1随机分配至铂类化疗(4周期)联合帕博利珠单抗组或铂类化疗(2周期)联合纳武利尤单抗-伊匹木单抗组。
- 主要终点为总生存期,在意向治疗人群(所有随机分配患者)中评估。
- 最终入组295例(男性236例[80%],女性59例[20%]),主要分析基于117例死亡(少于所需的329例死亡)。
主要发现
- 纳武利尤单抗-伊匹木单抗组148例中11例(7%)发生治疗相关死亡,因治疗相关死亡数量高而提前终止入组。
- 3级及以上非血液学不良事件在纳武利尤单抗-伊匹木单抗组为146例中87例(60%),帕博利珠单抗组为144例中59例(41%)。
- 帕博利珠单抗组生活质量相较纳武利尤单抗-伊匹木单抗组有更好趋势。
临床怎么用
- 对于晚期非小细胞肺癌一线治疗,帕博利珠单抗联合铂类化疗相较于纳武利尤单抗-伊匹木单抗联合铂类化疗可能具有更优的获益-风险特征。
- 使用纳武利尤单抗-伊匹木单抗联合铂类化疗时需警惕治疗相关死亡风险及更高的3级及以上非血液学不良事件发生率。
局限性
- 因治疗相关死亡数量高而提前终止入组,主要分析基于117例死亡,少于预设的329例死亡。
- 总生存期数据尚未成熟,最终结论有待更新分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of platinum-based chemotherapy and an antibody to PD-1 or to its ligand PD-L1, with or without an antibody to CTLA-4, has improved the survival of individuals with metastatic non-small-cell lung cancer (NSCLC). However, no randomised controlled trial has evaluated the survival benefit of adding a CTLA-4 inhibitor to platinum-based chemotherapy plus a PD-1 or PD-L1 inhibitor. METHODS: This open-label, randomised, phase 3 trial was conducted at 48 hospitals in Japan. Eligible patients were aged 20 years or older with previously untreated advanced NSCLC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients with known driver oncogenes were excluded. Participants were randomly assigned (1:1) to receive platinum-based chemotherapy (four cycles) plus pembrolizumab (pembrolizumab group) or platinum-based chemotherapy (two cycles) plus nivolumab-ipilimumab (nivolumab-ipilimumab group). The primary endpoint was overall survival and assessed in all randomly assigned patients on an intention-to-treat basis. The trial is registered in the Japan Registry for Clinical Trials, jRCTs031210013, and is now closed to new enrolment and is ongoing. FINDINGS: Between patient accrual initiation on April 6, 2021, and discontinuation of the trial on March 30, 2023, 11 (7%) of 148 patients in the nivolumab-ipilimumab group had a treatment-related death. Because of the high number of treatment-related deaths, patient accrual was terminated early, resulting in 295 patients (236 [80%] male and 59 [20%] female) enrolled; the primary analysis was done on the basis of 117 deaths (fewer than the required 329 deaths). By May 25, 2023 (data cutoff), overall survival did not differ significantly between the nivolumab-ipilimumab group and the pembrolizumab group (median 23·7 months [95% CI 17·6-not estimable] vs 20·5 months [17·6-not estimable], respectively; hazard ratio 0·98 [90% CI 0·72-1·34]; p=0·46). Non-haematological adverse events of grade 3 or worse occurred in 87 (60%) of 146 patients in the nivolumab-ipilimumab group and 59 (41%) of 144 patients in the pembrolizumab group. The pembrolizumab group tended to have a better quality of life compared with the nivolumab-ipilimumab group. INTERPRETATION: The safety and efficacy data suggest an unfavourable benefit-risk profile for nivolumab-ipilimumab combined with platinum-based chemotherapy relative to pembrolizumab combined with platinum-based chemotherapy as a first-line treatment for patients with advanced NSCLC, although a definitive conclusion awaits an updated analysis of overall survival. FUNDING: The National Cancer Center Research and Development Fund and Japan Agency for Medical Research and Development.
引用
- Shiraishi Y, Nomura S, Sugawara S, et al. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. Lancet Respir Med. 2024. PMID: 39159638. doi:10.1016/S2213-2600(24)00185-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。